literature

HIV mutation literature information.

Phase 2 Open-Label Study of Long-Term Safety, Tolerability, and Antiviral Activity of Rilpivirine in Antiretroviral-Naive Adolescents Living with HIV-1.

PMID: 34871089 2022 Antimicrobial agents and chemotherapy

Method: Patients with previously documented HIV-2 infection, with active AIDS, and with documented genotypic evidence of >=1 NNRTI resistance-associated mutation (RAM) from a predefined list of the following NNRTI RAMs at screening were excluded: A98G, L100I, K101E, K101P, K101Q, K103H, K103N, K103S, K103T, V106A, V106M, V108I, E138A, E138G,

Emergence of Resistance in HIV-1 Integrase with Dolutegravir Treatment in a Pediatric Population from the IMPAACT P1093 Study.

PMID: 34694878 2022 Antimicrobial agents and chemotherapy

Table: G190A

Doravirine: its role in HIV treatment.

PMID: 34740228 2022 Current opinion in HIV and AIDS

Abstract: Doravirine has a high genetic barrier to resistance with retained activity in the presence of single NNRTI mutations K103N, Y181C and G190A.

Deep sequencing of HIV-1 reveals extensive subtype variation and drug resistance after failure of first-line antiretroviral regimens in Nigeria.

PMID: 34741609 2022 The Journal of antimicrobial chemotherapy

Result: M184V was present in 87% of participants (88/101) at >=2% frequency, Y181C in 61% (62/101), K103N in 43% (41/101), M41L in 32% (32/101) and G190A in 31% (31/101).

Rising rates of recent preexposure prophylaxis exposure among men having sex with men newly diagnosed with HIV: antiviral resistance patterns and treatment outcomes.

PMID: 34873084 2022 AIDS (London, England)

Table: G190A/S

Brief Report: Bictegravir/Emtricitabine/Tenofovir Alafenamide Efficacy in Participants With Preexisting Primary Integrase Inhibitor Resistance Through 48 Weeks of Phase 3 Clinical Trials.

PMID: 34897227 2022 Journal of acquired immune deficiency syndromes (1999)

Table: G190A/E

Could Long-Acting Cabotegravir-Rilpivirine Be the Future for All People Living with HIV? Response Based on Genotype Resistance Test from a Multicenter Italian Cohort.

PMID: 35207677 2022 Journal of personalized medicine

Method: Furthermore, we excluded people with the following mutations for NNRTI: L100I, K101E/H/NP/Q, E138A/G/K/Q/R, V179L, Y181C/F/G/I/S/V, Y188L, G190A/C/E/Q/S/T/V, H221Y, F227C/L, and M230L.

Prevalence and patterns of HIV drug resistance in patients with suspected virological failure in North-Western Tanzania.

PMID: 35107140 2022 The Journal of antimicrobial chemotherapy

Abstract: Common mutations in RT were M184V (75%), T215Y (41.1%), K103N (39.3%), M41L (32.1%), <

Discussion: Likewise, the selection of NNRTI-associated mutations such as G190A and Y181C among patients on failing bPI ART regimens can be explained by either TDR-RAMs or by previous undisclosed exposure to NNRTI-based regimens.

Discussion: Some of the most common mutations in this study were M184V, K103N, Y181C and G190A, which occurred at similar frequencies to those reported in studies from other SSA and Tanzanian settings.

Biophysical Characterization of Novel DNA Aptamers against K103N/Y181C Double Mutant HIV-1 Reverse Transcriptase.

PMID: 35011517 2022 Molecules (Basel, Switzerland)

Introduction: A high prevalence of NNRTIs drug mutations was found in K103N, V106M, Y181C, and G190A.

Introduction: reported NVP induced K103N, Y181C, and G190A mutations.

Impact of low-level viremia with drug resistance on CD4 cell counts among people living with HIV on antiretroviral treatment in China.

PMID: 35509014 2022 BMC infectious diseases

Abstract: Of 925 patients with VL >= 1000 copies/mL, 495 (53.5%) acquired HIVDR, the most common DRAM were K103N 43.8%, M184I/V 43.2%, M41L 19.0%, D67N/G 16.4%, V181C/I/V 14.5%, G190A/S 13.9% and K101E 13.7% (multidrug resistance: 75.8%), and patients with HIVDR had a higher risk of CD4 cell counts < 200 cells/muL (AOR 5.8, 95% CI 4.6-7.4, p < 0.01) comparing with those without HIVDR.

Browser Board

Co-occurred Entities

Filtrator